UNITED LAB (03933): Moxifloxacin hydrochloride eye drops have been approved by the National Medical Products Administration for market authorization.

UNITED LAB (03933) announced that its wholly-owned subsidiary Zhuhai UNITED LAB Pharmaceutical Co., Ltd. Shan Branch has received approval from the China National Medical Products Administration for the market approval of Moxifloxacin Hydrochloride Eye Drops (specifications: 0.5% (3ml:15mg), 0.5% (5ml:25mg)). The drug approval numbers are H20256128 and H20256129 respectively. Moxifloxacin Hydrochloride belongs to the fourth generation of quinolone antibiotics, with a broad spectrum of antibacterial activity. Moxifloxacin Hydrochloride Eye Drops are used for the treatment of bacterial conjunctivitis caused by sensitive microorganisms such as Staphylococcus aureus, Hemophilus influenzae, and Moraxella catarrhalis. This product does not contain preservatives, avoiding the toxic effects of preservatives on eye tissues, making it suitable for a wide range of people. Currently, Moxifloxacin Hydrochloride Eye Drops are listed as Class B medicines in the national medical insurance catalogue (2024 version). This approval will further expand UNITED LAB's ophthalmology product portfolio, enhancing the company's leading position in the field of ophthalmic anti-infective treatment. The company will continue to focus on promoting new product development, providing comprehensive and high-quality medication solutions for clinical use, and is expected to create greater returns for the company and its shareholders.